Market Place
Sourcing Support
HanAll, Daewoong, NurrOn Complete 1st-in-Human Parkinson’s Study
25 Nov 2024 //
PR NEWSWIRE
Daewoong Pharmaceutical Unveils Innovative Drug Delivery Tech
09 Oct 2024 //
PR NEWSWIRE
Daewoong`s Bersiporocin Receives Positive IDMC Recommendation
29 Jul 2024 //
PR NEWSWIRE
Daewoong Presents Enavogliflozin`s Phase 3 Results At ADA Conference
19 Jun 2024 //
PR NEWSWIRE
Daewoong Pharmaceutical Announces 2023 Financial Results
06 Feb 2024 //
PR NEWSWIRE
Daewoong`s Bersiporocin Receives `Orphan Drug Designation` in Europe
29 Jan 2024 //
PR NEWSWIRE
HanAll, Daewoong and NurrOn to Showcase Ongoing Parkinson`s Disease Program
20 Dec 2023 //
PR NEWSWIRE
Zydus inks licensing agreement with Daewoong for leuprolide in the US
12 Dec 2023 //
INDIAN PHARMA POST
Daewoong to Initiate Trials Next Year for Innovative `GLP-1 Obesity Treatment
06 Nov 2023 //
PR NEWSWIRE
Daewoong Pharmaceutical Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
PR NEWSWIRE
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023
19 Oct 2023 //
PR NEWSWIRE
Daewoong Pharma and NurrOn Pharmaceuticals Initiate Phase 1 Study of HL192
12 Oct 2023 //
PR NEWSWIRE
Daewoong’s botulinum toxin wins `world’s 1st` nod to treat square jaw
28 Aug 2023 //
KOREA BIOMED
Daewoong Pharma steps into Africa`s digestive health market with $20.32M deal
26 Jul 2023 //
BIOSPECTRUM ASIA
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences
12 Jun 2023 //
PR NEWSWIRE
Daewoong Regaining Rights to Fexuprazan in the USA and Canada
05 Jun 2023 //
PR NEWSWIRE
Korea-US partnership to co-develop therapy for Parkinson`s Disease
26 May 2023 //
BIOSPECTRUM ASIA
Daewoong Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic
25 May 2023 //
PR NEWSWIRE
Daewoong Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023
19 May 2023 //
PR NEWSWIRE
Daewoong plots new $74.6M factory to pump out Botox rival
03 May 2023 //
FIERCE PHARMA
Company founded by ex-Novartis execs inks $477M in-license deal
28 Apr 2023 //
ENDPTS
Daewoong & Sygnature Discovery announce drug discovery research collaboration
18 Apr 2023 //
PR NEWSWIRE
M8 and Daewoong strengthen their partnership by signing agreement for Envlo
28 Feb 2023 //
PR NEWSWIRE
Envlo` of Daewoong , to be launched in markets entering the 1.54B USD Market
24 Feb 2023 //
PR NEWSWIRE
AEON Confirms Strategy for ABP-450 Unaffected by Korean Court
10 Feb 2023 //
GLOBENEWSWIRE
Daewoong Pharmaceutical begins the first administration of the Bersiporocin
06 Feb 2023 //
PR NEWSWIRE
Daewoong inks $336 M deal with CS Pharma for Idiopathic Pulmonary Fibrosis
01 Feb 2023 //
BIOSPECTRUM ASIA
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical
31 Jan 2023 //
ACCESSWIRE
Daewoong Pharma submitted NDA for its global new drug Fexuclue in 11 countries
25 Jan 2023 //
PR NEWSWIRE
Korea`s Daewoong Pharma aims to bring new diabetes drug in over 50 countries
08 Dec 2022 //
BIOSPECTRUMASIA
Daewoong Pharma announces success in developing a new antidiabetic medication
06 Dec 2022 //
PRNEWSWIRE
Daewoong Surpasses KRW 300B in Q3 Revenue as Nabota Sales Grew by 93%
15 Nov 2022 //
PRNEWSWIRE
HitGen inks research collaboration with Daewoong Pharma
15 Nov 2022 //
PHARMABIZ
Daewoong Presents Ph3 Trial Results of New Diabetes Treatment `Enavogliflozin`
01 Nov 2022 //
PRNEWSWIRE
Daewoong Pharma Announces US FDA Clearance of IND Application for DWP213388
15 Aug 2022 //
PRNEWSWIRE
Daewoong Pharma revs up the growth engine for Nabota
28 Jul 2022 //
PRNEWSWIRE
Daewoong Pharma Gets First Korean US FDA FTD for New IPF Drug
20 Jul 2022 //
PRNEWSWIRE
Daewoong Pharma begins multinational PII trial for DWN12088 for IPF
24 Jun 2022 //
PRNEWSWIRE
Daewoong applies for approving its GE reflux drug in 4 Latin American countries
23 May 2022 //
KOREABIOMED
Daewoong Pharmaceutical announced first-quarter 2022 results
05 May 2022 //
PRNEWSWIRE
South Korean firms lay focus on immune cell therapy
02 May 2022 //
KOREABIOMED
Daewoong to cooperate with AZ in launching hyperlipidemia in Asia
02 May 2022 //
KOREABIOMED
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies
12 Apr 2022 //
PRNEWSWIRE
Korean firms back US-based Turn Bio for mRNA therapies
12 Apr 2022 //
BIOSPECTRUMASIA
Daewoong Announces Successful Phase 3 Topline Results for Enavogliflozin TCT
25 Feb 2022 //
PRNEWSWIRE
Daewoong Posts Record Annual Revenue in 2021, with Export Growth of Nabota
21 Feb 2022 //
PRNEWSWIRE
Daewoong Pharma Released Positive Phase 3 Topline Results for Antidiabetic Drug
25 Jan 2022 //
PRNEWSWIRE
Medytox`s Patent Suit Against Daewoong Dismissed in U.S.
07 Oct 2021 //
YNA
Daewoong Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients
29 Jul 2021 //
PRNEWSWIRE
Neurogastrx Agreement with Daewoong Pharmaceutical to Develop Fexuprazan
08 Jun 2021 //
PRNEWSWIRE
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF)
27 May 2021 //
PRNEWSWIRE
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF)
27 May 2021 //
PRNEWSWIRE
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF)
27 May 2021 //
PRNASIA
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis (IPF)
24 May 2021 //
PRNEWSWIRE
Daewoong showed improved performance both sales and earnings in Q1
07 May 2021 //
PRNASIA
Daewoong clinches W380b out-licensing deal with Chinese pharmaceutical firm
18 Mar 2021 //
KOREANHERALD
Daewoong to start phase 3 trial of COVID-19 preventive
25 Jan 2021 //
KOREAHERALD
Daewoong to initiate phase 3 trial of camostat in combination with remdesivir
04 Jan 2021 //
FIRSTWORDPHARMA
South Korea Daewoong Pharma eyes Phase II trials of coronavirus drug
04 Dec 2020 //
REUTERS
Daewoong to repurpose Foistar as COVID-19 treatment by January
23 Nov 2020 //
KOREAHERALD
